Novartis pay-for-silence retreat is first of many
Finding the limit
In the face of public fury, the Swiss drugmaker has cancelled $78 mln in non-compete payments to its retiring chairman. Daniel Vasella’s case was extreme: ultra-high reward for essentially no action in an egalitarian land. But it sets a strong precedent for activists everywhere.